Multiple myeloma (MM) affected 14,400 new individuals in the United States in 2001, with 50,000 total patients, and remains incurable despite conventional and high dose therapies. Novel therapeutic interventions are therefore urgently needed with targets unique to the tumor cell and its microenvironment. The major goal of the current proposal, """"""""Host-Tumor Cell Interactions in Myeloma: Therapeutic Applications"""""""", is to develop novel therapies targeting host-tumor cell interactions to overcome drug resistance and achieve long-term disease free survival and potential cure of MM. This Program builds upon and extends progress during the prior funding period and now has three major goals. First, we will attempt to therapeutically exploit the interaction of the allogeneic donor immune response against MM and define target antigens for novel therapeutics (Project by Ritz). Second, we will attempt to augment autologous anti-MM immunity using vaccination strategies, and similarly identify novel target antigens (Project by Munshi). In each case molecular identification and validation of novel targets will derive MM specific immune therapies. Importantly, our preclinical in vitro as well as in vivo animal models of MM cells in the BM milieu, demonstrate that novel agents targeting the MM cell-host bone marrow (BM) interaction can overcome classical drug resistance. Our derived clinical trials show that these agents can achieve responses, in some cases complete responses, in the majority of patients with MM refractory to all known current therapies. Therefore a new and important goal of this Program (Project by Anderson) is to define and validate MM-host interactions as targets in a new treatment paradigm for MM. Administrative and Research Nursing (A) and Biostatistics/ Bioinfomatics (B) Cores will assist in design, conduct, analysis, and reporting of laboratory and clinical studies. Immune Assessment Core (C) will provide immunological monitoring after these novel therapies. This Program therefore represents an integrated, interrelated, and interdependent series of three Projects and three Cores which interact on both a scientific and clinical level. It is anticipated, both within and between projects, that laboratory based mechanistic studies will translate to clinical studies, and that conversely, observations from clinical protocols will suggest new basic investigations. Ultimately our goal is to validate MM-host cell interactions as a target for novel therapeutics to improve patient outcome in MM.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA078378-09
Application #
7081422
Study Section
Special Emphasis Panel (ZCA1-GRB-2 (M1))
Program Officer
Wu, Roy S
Project Start
1998-08-01
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
9
Fiscal Year
2006
Total Cost
$2,020,671
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tai, Yu-Tzu; Lin, Liang; Xing, Lijie et al. (2018) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia :
Bae, J; Hideshima, T; Zhang, G L et al. (2018) Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia 32:752-764
Pyzer, Athalia Rachel; Stroopinsky, Dina; Rajabi, Hasan et al. (2017) MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 129:1791-1801
Cholujova, Danka; Bujnakova, Zdenka; Dutkova, Erika et al. (2017) Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol 179:756-771
Yin, Li; Tagde, Ashujit; Gali, Reddy et al. (2017) MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol 178:914-926
Harada, T; Ohguchi, H; Grondin, Y et al. (2017) HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia 31:2670-2677
Hideshima, Teru; Cottini, Francesca; Nozawa, Yoshihisa et al. (2017) p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood 129:1308-1319
Ohguchi, H; Harada, T; Sagawa, M et al. (2017) KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia 31:2661-2669
Feng, Xiaoyan; Zhang, Li; Acharya, Chirag et al. (2017) Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res 23:4290-4300
Bar-Natan, Michal; Stroopinsky, Dina; Luptakova, Katarina et al. (2017) Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol 176:929-938

Showing the most recent 10 out of 270 publications